[Investigation of fatty acid composition for identification of clinical isolates of Pseudomonas spp].

The use of commercial test-systems has not allowed to identify 11 atypical clinical strains of nonfermenting Gram-negative bacteria. The divergences arised not only under their species identification, but also under generic one. On the basis of studying the fatty acid composition of the cell wall all isolates were referred to Pseudomonas genus. The further control of species belonging of the strains carried out with the use of 45 tests and the computer program www.imv.kiev.ua/PsmIK/default.htm has confirmed, that five isolates are representatives of P. aeruginosa, two ones were identified as P. fluorescens, and three more as Pseudomonas spp.

[Property of collection strains and new isolates of Shigella sonnei].

The vital ability, serological properties, antibioticograms and biochemical properties of collection strains and new isolates of Shigella sonnei have been studied. It was ascertained that the determined factors are sufficiently variable, thus they cannot be used as the independent basis for the classification of pathogens.

[Change of serological properties of museum strains of Shigella flexneri in different terms of storage].

The viability, purity, biological and serological properties of museum strains of Shigella flexneri which were kept in lyophilized state during above 30 years were studied. Primary serological characteristics were specified, it was established that type 2a is the predominant serotype independent of the years and regions of isolation. Some strains lost antigens as a result of the long-term preservation or reinoculation on agar media.

[Laboratory and clinical study of nitazole]. / Laboratorno-klinicheskoe izuchenie nitazola.

Nitazole, a drug from the nitrotiazole group, was shown to be active in vitro against bacteroides, peptococci, peptostreptococci, clostridia, staphylococci, colibacilli and streptococci. By its activity and antibacterial spectrum nitazole had some advantages over metronidazole, a drug from the nitroimidazole group. Experimental study of nitazole aerosole formulation in 4 models of purulent wounds of rabbits infected by Bacteroides fragilis, B. melaninogenicus, Clostridium perfringens 27 and Staphylococcus aureus 209P revealed its high therapeutic efficacy. In the treatment of 37 patients with purulent wounds of the soft tissues including 12 cases isolating anaerobic microbes, the clinical process of the acute suppuration in all the patients at the average reduced to the 5th-7th day. By the data of the bacteriological and cytological examinations the wound surface was ready for putting in stitches or free perforated cutaneous graft by the 10th-12th day. The drug tolerance was good. No adverse reaction were observed under the nitazole dressing in any case during the treatment of the wounds.

[Antibacterial activity of some trichomonacidal agents]. / Antibakterial'naia aktivnost' nekotorykh trikhomonatsidnykh sredstv.

In vitro and in vivo antibacterial activity of metronidazole preparations was studied in comparison to that of nitazole in various dosage forms: solution, aerosol, suspension and suppository. The metronidazole preparations inhibited only anaerobic organisms and were efficient in experimental infections caused by them. Unlike the metronidazole preparations, the dosage forms of nitazole inhibited the growth not only of anaerobic organisms but also that of staphylococci and had a therapeutic effect on infections caused by these organisms.

[Experimental and clinical study of nitazol as an antibacterial drug in the complex treatment of peritonitis]. / Eksperimental'no-klinicheskoe izuchenie nitazola kak antibakterial'nogopreparata v kompleksnom lechenii peritonitov.

Antibacterial properties of the Soviet drug nitazol which is a derivative of imidazole were studied. It was shown that nitazol in a dose of 4-8 micrograms/ml was highly active against gram-negative nonsporulating anaerobes, gram-positive anaerobic cocci and spore-forming Clostridia spp. Unlike metronidazole, it was efficient against both standard and clinical strains of facultative anaerobes such as E. coli, S. aureus and Klebsiella spp. isolated from patients with peritonitis and being poly-resistant to antibiotics. It was found in vitro that the antibacterial effect of nitazol was higher when it was used in combination with some antibiotics. It was demonstrated on experimental models of peritonitis caused by Staphylococcus spp. and E. coli in mice that nitazol used alone or in combination with gentamicin had a favourable effect on the animal survival and lifespan. The combination of nitazol with gentamicin was applied in the combined treatment of appendicular peritonitis in 80 children and its high therapeutic efficacy was stated. Nitazol is useful as an antibacterial drug in the combined treatment of children with purulent peritonitis.

[Antibacterial activity of nitazole and its use in combined treatment of appendicular peritonitis in children]. / Antibakterial'naia aktivnost' nitazola i primenenie ego v kompleksnom lechenii appendikuliarnogo peritonita u detei.

The experimental-clinical investigations have demonstrated the high effectiveness of the native preparation Nitazole against the Gram-negative non-spore-forming anaerobic bacteria, Gram-positive anaerobic cocci, spore-forming Clostridium, certain facultative anaerobes. This permits to recommend it for the use as an antibacterial preparation for the treatment of peritonitis in children.